August 2007

Intraocular Pressure FluctuationAn Independent Risk Factor for Glaucoma?

Author Affiliations

Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2007

Arch Ophthalmol. 2007;125(8):1124-1125. doi:10.1001/archopht.125.8.1124

Prospective, randomized, clinical trials of glaucoma treatment have convincingly shown the efficacy of intraocular pressure (IOP) reduction to slow the progression of glaucomatous optic nerve damage. Prospective, randomized, long-term studies have covered a spectrum of disease from early to late, and from normal to high pressures.13 Others included a comparison of medical vs surgical treatment,4 and even treatment vs no treatment.5 All have demonstrated the strength of IOP reduction to slow the progression of disease, as measured by visual function and optic nerve structure. There is no longer any doubt (though some of us never doubted) that robust IOP reduction works in most patients.

First Page Preview View Large
First page PDF preview
First page PDF preview